Trevi Therapeutics, Inc. announced that it has received $71.557999 million in funding from TPG Biotech, New Enterprise Associates, Aperture Venture Partners, LLC, Lundbeckfond Invest A/S, Omega Fund Management, LLC and other investors
January 18, 2019
Share
On January 18, 2019, Trevi Therapeutics, Inc. closed the transaction. The company has received $71,557,999.68 in the transaction. The company announced that it has issued 6,849,315 shares for gross proceeds of $9,999,999.9 in its sixth and final tranche. The company incurred issuance costs of $34 with respect to the the tranche.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
Trevi Therapeutics, Inc. announced that it has received $71.557999 million in funding from TPG Biotech, New Enterprise Associates, Aperture Venture Partners, LLC, Lundbeckfond Invest A/S, Omega Fund Management, LLC and other investors
TREVI THERAPEUTICS, INC. 
